Dronabinol Patent Expiration
Dronabinol was first introduced by Alkem Laboratories Ltd
Dronabinol Patents
Given below is the list of patents protecting Dronabinol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Syndros | US10265293 | Oral cannabinoid formulations | Aug 06, 2028 | Wellhouse Pharma |
| Syndros | US11253472 | Oral cannabinoid formulations | Aug 06, 2028 | Wellhouse Pharma |
| Syndros | US8222292 | Liquid cannabinoid formulations | Aug 06, 2028 | Wellhouse Pharma |
| Syndros | US9345771 | Oral cannabinoid formulations | Aug 06, 2028 | Wellhouse Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dronabinol's patents.
Latest Legal Activities on Dronabinol's Patents
Given below is the list recent legal activities going on the following patents of Dronabinol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Jun, 2025 | US11253472 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 20 Nov, 2023 | US8222292(Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Jul, 2022 | US10265293 |
| Email Notification Critical
| 20 Jul, 2022 | US10265293 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 20 Jul, 2022 | US10265293 |
| Correspondence Address Change Critical
| 19 Jul, 2022 | US10265293 |
| Patent Issue Date Used in PTA Calculation Critical
| 22 Feb, 2022 | US11253472 |
| Recordation of Patent Grant Mailed Critical
| 22 Feb, 2022 | US11253472 |
| Email Notification Critical
| 03 Feb, 2022 | US11253472 |
| Issue Notification Mailed Critical
| 02 Feb, 2022 | US11253472 |
Dronabinol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Dronabinol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Synthetic THC And Blood Pressure | Mayo Clinic | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| A Study Of Synthetic THC And Sleep | Mayo Clinic | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| Endocannabinoids in Reward | Medical University of South Carolina | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Reducing Breathlessness With Dronabinol in COPD Patients | Vejle Hospital | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| DRonabinol Treatment of OSA | VA Office of Research and Development | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Dronabinol After Arthroscopic Surgery | Northwestern University | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| Sex Differences in Neurobehavioral Response to THC | Medical University of South Carolina | NA |
TERMINATED
(May 1, 2026)
| PHASE2 |
| Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III | Yale University | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE1 |